Business Wire

Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration

CHICAGO--(BUSINESS WIRE)--Celltrion USA today announced the submission of a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act (a “stand-alone” BLA) for ...
Medscape

Woman on Insulin Develops Injection-Site Amyloidosis

Repeated insulin shots at the same site can seed amyloid; consider this diagnosis if absorption seems erratic or glucose control worsens with a persistent lump.
Business Wire

Celltrion Healthcare showcases initial data from year-long study for subcutaneous formulation of CT-P13 (biosimilar infliximab) in patients with Crohn’s disease

COPENHAGEN, Denmark--(BUSINESS WIRE)--New data presented at the 14th congress of European Crohn’s and Colitis Organisation (ECCO) show that the subcutaneous (SC) formulation of CT-P13 is comparable in ...
Healio

More than 60% of Crohn’s patients sustained remission with subcutaneous biosimilar CT-P13

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio CHICAGO — Subcutaneous maintenance ...
Monthly Prescribing Reference

Subcutaneous Formulation of Infliximab Biosimilar CT-P13 Investigated in RA Patients

Results from the first study showed the overall efficacy at week 54 and the safety profile at week 6 of CT-P13 SC were comparable to CT-P13 IV. Celltrion Healthcare presented new findings at the ...